Dear Managed Care Colleagues,

Welcome to our summer 2023 issue of the Magellan Rx Report!

So far in 2023, the FDA has approved 26 novel drugs, with many more anticipated by year’s end. Exciting advancements and innovative therapies contribute to a promising, expansive pipeline across disease categories. We are committed to bringing our audience valuable, timely highlights of managed care trends and treatment updates.

Our cover story (page 14) focuses on the exciting advances in gene therapy. We review the gene therapies recently approved by the FDA, discussing the current landscape and highlighting management strategies around these high-cost treatments. The article also outlines the pipeline in this category.

Another article focuses on updates in bladder cancer treatment. Recent approvals in the space, including the first gene therapy for bladder cancer, will shift the landscape. We outline the pipeline in this category as well as the financial and payer impact of new approvals.

In our enzyme replacement therapy (ERT) article (page 6), we highlight the recent growth in the ERT landscape. Given that this market is anticipated to grow significantly over the next decade, management strategizing will become increasingly important.

Other topics in this issue include a discussion of recent advances in the treatment of amyotrophic lateral sclerosis (page 10), a dive into the impact of the FDA accelerated approval program (page 24), and a look at results from a real-world CMS Star Rating clinical program (page 30). As always, the issue is rounded out by our pipeline update (page 34) and managed care newsstand (page 4).

To learn more about our support for payer initiatives of the future, please feel free to contact us at MagellanRxReport@ magellanhealth.com. As always, we value any feedback you may have. I hope you enjoy the report!

Sincerely,

Mostafa Kamal Chief Executive Officer Magellan Rx Management

We hope you enjoy the issue; thank you for reading.